ThyroSafe

Manufacturer
Recipharm AB (publ) | Recipharm Fontaine
Effective date
2021-11-30
Label type
HUMAN OTC DRUG LABEL
Version
3
Source
full-release
Hydrated at
2026-05-31 23:45:13

Label at a glance#

ProductThyroSafe
Active ingredientPotassium Iodide
Label structure11 sections

Dosage and administration

use as directed by public officials in the event of a nuclear radiation emergency do not take more than 1 dose in 24 hours tablets can be whole or crushed and mixed in milk, baby formula, water, orange juice, flat soda like cola, or raspberry syrup. The liquid mixture should be given to infants, young children, and others who cannot swallow tablets; see consumer package insert on how to make a liquid mixture. adul...

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

Drug Facts

Active Ingredient (in each tablet)

OTC - ACTIVE INGREDIENT SECTION

Potassium Iodide 65 mg

Purpose

OTC - PURPOSE SECTION

Thyroid blocking

INDICATIONS & USAGE SECTION

Use helps prevent radioactive iodine from getting into the thyroid gland during a nuclear radiation emergency.

Use along with other emergency measures recommended by public officials.

Warnings

WARNINGS SECTION

SPL UNCLASSIFIED SECTION

Allergy alert: Iodine may cause an allergic reaction with 1 or more of the following symptoms:

  • shortness of breath or wheezing
  • swelling
  • skin rash
  • trouble breathing, speaking or swallowing
  • fever and joint pain

OTC - DO NOT USE SECTION

Do not use if you have

  • ever had an allergic reaction to iodine
  • nodular thyroid disease with heart disease
  • hypocomplementemic vasculitis
  • dermatitis herpetiformis

OTC - STOP USE SECTION

Stop use and ask a doctor if you have

  • allergic reaction. Get medical help right away if you have trouble breathing, speaking or swallowing; shortness of breath; wheezing; swelling of the mouth, tongue or throat; or rash.
  • irregular heart or chest pain. Get medical help right away.
  • swelling of the hands or feet, fever, or joint pain

OTC - KEEP OUT OF REACH OF CHILDREN SECTION

Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away.

Directions

DOSAGE & ADMINISTRATION SECTION

  • use as directed by public officials in the event of a nuclear radiation emergency
  • do not take more than 1 dose in 24 hours
  • tablets can be whole or crushed and mixed in milk, baby formula, water, orange juice, flat soda like cola, or raspberry syrup. The liquid mixture should be given to infants, young children, and others who cannot swallow tablets; see consumer package insert on how to make a liquid mixture.
adults over 18 years 2 tablets (whole or crushed) daily (130 mg)
children over 12 years to 18 years who weigh at least 150 pounds 2 tablets (whole or crushed) daily (130 mg)
children over 12 years to 18 years who weigh less than 150 pounds 1 tablet (whole or crushed) daily (65 mg)
children over 3 years to 12 years 1 tablet (whole or crushed) daily (65 mg)
children over 1 month to 3 years 1/2 tablet (crushed) daily (32.5 mg)
babies at birth to 1 month 16.25 mg daily as directed in consumer package insert

OTC - PREGNANCY OR BREAST FEEDING SECTION

  • if pregnant, breastfeeding, have a baby up to 1 month of age, or have thyroid disease (except nodular thyroid disease with heart disease), take as directed above and contact a doctor as soon as possible

Other information

OTHER SAFETY INFORMATION

  • store at 20-25° C (68-77° F)
  • keep dry and foil intact
  • protect from light
  • do not throw away consumer package insert

Inactive ingredients

INACTIVE INGREDIENT SECTION

lactose, magnesium stearate, microcrystalline cellulose

Questions or comments?

OTC - QUESTIONS SECTION

call toll free 1-866-849-7672

Principal Display Panel - 65 mg Carton Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC-66983-350-20

ThyroSafe®

Potassium Iodide Tablets, USP, 65 mg

Thyroid blocking in a radiation emergency only

20 tablets, 65 milligrams each

Recipharm

Principal Display Panel - 65 mg Carton Label
Principal Display Panel - 65 mg Carton Label

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
430174potassium iodide 65 MG Oral TabletPSN3
1086474ThyroSafe 65 MG Oral TabletPSN3
1086474potassium iodide 65 MG Oral Tablet [ThyroSafe]SBD3
430174potassium iodide 65 MG Oral TabletSCD3
430174K+ Iodide 65 MG Oral TabletSY3
1086474K+ Iodide 65 MG Oral Tablet [ThyroSafe]SY3
430174Pot Iodide 65 MG Oral TabletSY3
1086474Pot Iodide 65 MG Oral Tablet [ThyroSafe]SY3
1086474ThyroSafe 65 MG Oral TabletSY3

FDA-Initiated Inactive NDC Indexing#

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
66983-350-20ThyroSafe20 in 1 BOXTABLET203
66983-350-20ThyroSafe160 in 1 CARTONTABLET1603

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
66983-350THYROSAFE (POTASSIUM IODIDE) TABLET [RECIPHARM AB (PUBL)]3Legacy NDC, 2 package rows20211201_4f577f7a-4390-488c-b327-13a32e06be04.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
66983-350-20EA - Each66983-3504f18c198-40b2-493e-b681-46d3821fba5812016-06-14

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 6 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
66983-35066983-350-20

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 4 matching rows.

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 44.

Orange Book products#

Current product rows page 1 of 1 · 2 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A076350-001THYROSAFEPOTASSIUM IODIDE65MGTABLET / ORALRS2002-09-10
A076350-002THYROSAFEPOTASSIUM IODIDE130MGTABLET / ORAL2025-04-02

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 51 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-10-15 13:18:302026-09A076350-001THYROSAFE65MGTABLET / ORALRS2002-09-10c2088c7a36db…
2026-10-15 13:18:302026-09A076350-002THYROSAFE130MGTABLET / ORAL2025-04-02c2088c7a36db…
2026-09-14 22:38:342026-08A076350-001THYROSAFE65MGTABLET / ORALRS2002-09-1084e616aacf4f…
2026-09-14 22:38:342026-08A076350-002THYROSAFE130MGTABLET / ORAL2025-04-0284e616aacf4f…
2026-08-18 06:07:402026-07A076350-001THYROSAFE65MGTABLET / ORALRS2002-09-10caaa826d4ba7…
2026-08-18 06:07:402026-07A076350-002THYROSAFE130MGTABLET / ORAL2025-04-02caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A076350-001THYROSAFE65MGTABLET / ORALRS2002-09-10011fe1cb6892…
2026-02-19 14:30 UTC2026-02A076350-002THYROSAFE130MGTABLET / ORAL2025-04-02011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A076350-001THYROSAFE65MGTABLET / ORALRS2002-09-1031067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A076350-002THYROSAFE130MGTABLET / ORAL2025-04-0231067a03dcf5…
2025-08-23 18:47 UTC2025-08A076350-001THYROSAFE65MGTABLET / ORALRS2002-09-106a471c1ec25d…
2025-08-23 18:47 UTC2025-08A076350-002THYROSAFE130MGTABLET / ORAL2025-04-026a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A076350-001THYROSAFE65MGTABLET / ORALRS2002-09-10fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A076350-001THYROSAFE65MGTABLET / ORALRS2002-09-10b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A076350-001THYROSAFE65MGTABLET / ORALRS2002-09-1003ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A076350-001THYROSAFE65MGTABLET / ORALRS2002-09-102680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A076350-001THYROSAFE65MGTABLET / ORALRS2002-09-105bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A076350-001THYROSAFE65MGTABLET / ORALRS2002-09-10d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A076350-001THYROSAFE65MGTABLET / ORALRS2002-09-10d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A076350-001THYROSAFE65MGTABLET / ORALRS2002-09-1079d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A076350-001THYROSAFE65MGTABLET / ORALRS2002-09-10301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A076350-001THYROSAFE65MGTABLET / ORALRS2002-09-101e350fbaab3a…
2024-05-31 18:47 UTC2024-05A076350-001THYROSAFE65MGTABLET / ORALRS2002-09-108072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A076350-001THYROSAFE65MGTABLET / ORALRS2002-09-105c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A076350-001THYROSAFE65MGTABLET / ORALRS2002-09-105d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A076350-001THYROSAFE65MGTABLET / ORALRS2002-09-104b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A076350-001THYROSAFE65MGTABLET / ORALRS2002-09-1074a2ff9319b5…
2022-03-09 01:35 UTC2022-03A076350-001THYROSAFE65MGTABLET / ORALRS2002-09-10bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A076350-001THYROSAFE65MGTABLET / ORALRS2002-09-10782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A076350-001THYROSAFE65MGTABLET / ORALRS2002-09-1087673890dc5c…
2021-03-12 10:30 UTC2021-03A076350-001THYROSAFE65MGTABLET / ORALRS2002-09-105aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A076350-001THYROSAFE65MGTABLET / ORALRS2002-09-108869cabd3fbd…
2020-11-12 02:37 UTC2020-11A076350-001THYROSAFE65MGTABLET / ORALRS2002-09-10c0c555d07b60…
2019-12-14 00:12 UTC2019-12A076350-001THYROSAFE65MGTABLET / ORALRS2002-09-103f01610625f2…
2019-09-15 20:21 UTC2019-09A076350-001THYROSAFE65MGTABLET / ORALRS2002-09-10b00525d2431f…
2019-07-19 19:46 UTC2019-07A076350-001THYROSAFE65MGTABLET / ORALRS2002-09-10ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A076350-001THYROSAFE65MGTABLET / ORALRS2002-09-106a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A076350-001THYROSAFE65MGTABLET / ORALRS2002-09-101c564ffb4f44…
2023-12-20 04:57 UTC2023-12A076350-001THYROSAFE65MGTABLET / ORALRS2002-09-10ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A076350-001THYROSAFE65MGTABLET / ORALRS2002-09-10a72a2bbeb626…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
7a03a65b-330b-4d71-a445-c66eda195a034f577f7a-4390-488c-b327-13a32e06be042021-11-30WarningsExact identifier
spl id: 7a03a65b-330b-4d71-a445-c66eda195a03
spl set id: 4f577f7a-4390-488c-b327-13a32e06be04

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.